SciClone To Present At 27th Annual Piper Jaffray Healthcare Conference On December 2, 2015

17 Nov, 2015, 06:00 ET from SciClone Pharmaceuticals, Inc.

FOSTER CITY, Calif., Nov. 17, 2015 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Friedhelm Blobel, PhD, Chief Executive Officer, will present a corporate overview and business update at the 27th Annual Piper Jaffray Healthcare Conference at 10:30 am ET on Wednesday, December 2, 2015, at the New York Palace Hotel in New York City.   

To access the live audio webcast of this presentation, please log on through a link located in the Investor Relations section of SciClone's website at www.sciclone.com, under the Calendar of Events tab. A replay of the webcast will be available one hour after the conclusion of the live event.

About SciClone

SciClone Pharmaceuticals is a revenue-generating, specialty pharmaceutical company with a substantial commercial business in China and a product portfolio spanning major therapeutic markets including oncology, infectious diseases and cardiovascular disorders. SciClone's proprietary lead product, ZADAXIN® (thymalfasin), is approved in over 30 countries and may be used for the treatment of hepatitis B (HBV), hepatitis C (HCV), and certain cancers, and as a vaccine adjuvant, according to the local regulatory approvals. The Company has successfully in-licensed and commercialized products with the potential to become future market leaders and to drive the Company's long-term growth, including DC Bead®, a novel treatment for liver cancer. Through its promotion business with pharmaceutical partners, SciClone also markets multiple branded products in China which are therapeutically differentiated. SciClone is a publicly-held corporation based in Foster City, California, and trades on the NASDAQ Global Select Market under the symbol SCLN. For additional information, please visit www.sciclone.com.

Forward-Looking Statements

This press release contains forward-looking statements regarding expected financial results and expectations. Readers are urged to consider statements that include the words "may," "will," "would," "could," "should," "might," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," "unaudited," "approximately" or the negative of those words or other comparable words to be uncertain and forward-looking. These statements are subject to risks and uncertainties that are difficult to predict and actual outcomes may differ materially.  Please also refer to other risks and uncertainties described in SciClone's filings with the SEC. All forward-looking statements are based on information currently available to SciClone and SciClone assumes no obligation to update any such forward-looking statements.

SciClone, SciClone Pharmaceuticals, the SciClone Pharmaceuticals design, the SciClone logo and ZADAXIN are registered trademarks of SciClone Pharmaceuticals, Inc. in the United States and numerous other countries.

Corporate Contacts

Wilson W. Cheung 

Jane Green  

Chief Financial Officer 

Investors/Media

650.358.3434 

650.358.1447

wcheung@sciclone.com 

jgreen@sciclone.com

Logo - http://photos.prnewswire.com/prnh/20150722/240358LOGO

 

SOURCE SciClone Pharmaceuticals, Inc.



RELATED LINKS

http://www.sciclone.com